Responses
Clinical/translational cancer immunotherapy
Original research
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
